New-onset graves’ disease after the initiation of nivolumab therapy for gastric cancer: a case report

BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs) including thyroid dysfunction. There are only a few reports on Graves’ disease induced by ICIs. We report a case of new-onset Graves’ disease after the initiation of nivolumab therapy in a patient receiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Hiroshi, Okajima, Fumitaka, Onda, Takeshi, Fujimori, Shunji, Emoto, Naoya, Sugihara, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449083/
https://www.ncbi.nlm.nih.gov/pubmed/32847555
http://dx.doi.org/10.1186/s12902-020-00613-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449083/
https://www.ncbi.nlm.nih.gov/pubmed/32847555
http://dx.doi.org/10.1186/s12902-020-00613-5

Ejemplares similares